View Article Online View Journal

# Organic & Biomolecular Chemistry

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: R. Liu, P. Sharma, P. D. Jadhav and M. Skaria, *Org. Biomol. Chem.*, 2017, DOI: 10.1039/C7OB02087B.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the **author guidelines**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the ethical guidelines, outlined in our <u>author and reviewer resource centre</u>, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.



rsc.li/obc



# **Organic & Biomolecular Chemistry**

# ARTICLE

Received 00th January 20xx,

Accepted 00th January 20xx DOI: 10.1039/x0xx00000x

www.rsc.org/

Stereoselective annulation between an allene, an alkene, and two nitrosoarenes to access bis(isoxazoliodine) derivatives

Pankaj Sharma,<sup>a+</sup> Prakash D. Jadhav,<sup>a+</sup> Manisha Skaria,<sup>a</sup> and Rai-Shung Liu<sup>a,</sup>\*

**Abstract:** This work reports metal-free annulations between one allene, two nitrosoarenes and one electron-deficient alkene to afford bis(isoxazolidine) derivatives stereoselectively. This process involves an initial formation of isoxazolidin-4imine oxides, followed by their dipolar [3+2]-cycloaddition with electron-deficient alkenes. To highlight the utility, the annulations of 5-alleneyl-1-enes with nitrosoarenes were also feasible to afford desired bis(isoxazolidine) products with excellent stereocontrol. Resulting bis(isoxazolidine) products produced from two systems were reduced with Zn/MeOH to induce reductive N-O cleavages, yielding branched polyaminols stereoselectively.

# Introduction

Radical annulations via diradical intermediates are well documented in the literatures, but their utilities are poorly explored.<sup>1</sup> Diradical annulations typically employ hazardous diazo<sup>2-3</sup> and special precursors,<sup>4</sup> thus lacking general utility. Although commonly used  $\pi$ -bond motifs generate diradicals thermally, as exemplified with Bergman (eq 1) and Myers-Saito reactions, their utility is restricted to intramolecular aromatizations.<sup>5</sup> The formation of reactive 1,*n*-diradicals from readily available alkenes, alkynes, and allenes to enable diverse annulations is highly desirable in synthetic chemistry.

Nitrosoarenes are powerful reagents for the *N*,*O*-functionalizations of dienes, and alkynes via Lewis acidcatalyzed annulatios.<sup>6-7</sup> Theoretical calculations by Houk<sup>8,9</sup> suggest that the reactions of nitrosoarenes with alkenes or alkynes likely generate 1,4-diradicals, which cannot be synthetically utilized because of their transient nature. In the context of arylallenes, we recently reported<sup>10</sup> their reactions with nitrosoarenes to generate 1,4-diradical species I that were detectable by EPR (eq 2). Such 1,4-diradicals I can be trapped by ground-state O<sub>2</sub> to yield 1,2-dioxolanes **3** below 0 °C (eq 2); otherwise, diradicals I accept a second nitrosoarene to yield isoxazolidin-4-imine oxides **4** (eq 3).

To expand the utility of such 1,4-diradicals, this work<sup>10</sup> reports one-pot annulations between one allene, two nitrosoarenes and one olefin, yielding bis(isoxazolidine) species **5** with high stereoselectivity. This reaction sequence

Previous reports:



This work: Diradicals for four component annulations



generates isoxazolidin-4-imine oxides **4** initially, followed by their dipolar [3+2]-cycloadditions with electron-deficient alkenes. Importantly, the reductive N-O cleavage of resulting bis(isoxazolidine) species **4** provides branched polyaminols with high stereocontrol. Notably, readily available 5-allenyl-1enes were treated with nitrosoarenes under ambient conditions to yield bis(isoxazolidine) derivatives stereoselectively, further highlighting the synthetic utility.

Many bioactive molecules comprise not only one nitroxy ring, but also amino and alcohol functionalities; selected examples I-VI are depicted in Figure 1.<sup>11</sup> A rapid synthesis of these highly *N,O*-functionalized molecules is synthetically challenging. We envisage that one-pot stereoselective construction of a bicyclic ring bearing two N-O moieties is a

<sup>&</sup>lt;sup>a</sup>Department of Chemistry, National Tsing-Hua University, Hsinchu, Taiwan, ROC-30013. email address: <u>rsliu@mx.nthu.edu.tw</u>

<sup>†</sup> These two authors share equal contributions.

Electronic Supplementary Information (ESI) available: [details of any

#### 9-anthry 9-phenanthry 1-pyrenyl H<sub>2</sub>C ŌН NH<sub>3</sub> ш ш Potential DNA Acivicin (+) Clausenamide Intercalators OOH HC Ōн **NRR** Ő $\bar{\bar{N}}H_2$ IV vi Uronic acid-type Oseltamivi Saguinavi iminosugar

Figure 1. Representatives of several bioactive molecules

viable route. In this work, a successive N-O cleavage of two nitroxy rings of resulting bis(isoxazolidine) products 5 to afford polyaminols is also described.

# **Results and Discussion**

Unlike 1,2-dioxolanes **3**, the nitrone functionality of isoxazolidin-4-imine oxides 4 can undergo intermolecular [3+2]-cycloadditions with electron-deficient alkenes stereoselectively. Compound 4a was prepared in two isomeric ratios, E/Z = 1/1 and E/Z = 15/1, respectively at 25 °C and 0 °C, according to eq 3. To exploit the alkene cycloaddition, an E/Z =1:1 mixture of compound 4a was treated with ethyl acrylate to afford bis(isoxazolidine) compound 5a as a single





Journal Name

group decreases their cycloaddition reactivity. The molecular structure of compound **5a** was confirmed<sup>39</sup>/with<sup>B0</sup>%<sup>Q</sup>Pay diffraction.<sup>12</sup> An analysis of this X- ray structure revealed a preferable exo-3,5-cycloaddition of the alkene with Econfigured 4a; the nitrone oxygen is linked at the C-CO2Et carbon. This 3,5-regioselectivity (eq 5) typically occurs with unsubstituted enol ethers<sup>13</sup> and substituted electron-deficient alkenes such as ethyl E-but-2-enolate.<sup>14</sup> Unsubstituted 2-en-1ones and 2-en-1-als preferable afford 3,4-regioisomers instead. Our 3,5-regioselectivity is rationalized with a steric effect such that a large isoxazolidine ring is preferably attacked with an alkene end to result in a 3,5-regioselectivity. The overlap between nitrone and alkene is controlled by a less hindered exo-face with the alkene lying away the phenyl group, as depicted in TS-1 or TS-1'. The feasible Z-E isomerization of isoxazolidin-4-imine oxide 4a indicates the contribution of an alternative resonance form, as in state TS-1', in which the negative carbon terminus is stabilized with the adjacent oxygen and nitrogen atoms. Our next aim was to achieve a one-pot operation involving an initial treatment of allene **1g** with nitrosobenzene **2a** (4 equiv) in cold THF (0  $^{\circ}$ C, 3 h) to complete the consumption of allene 1a; to this resulting

Table 1. One-pot synthesis of bicyclic isoxazolidines.



 $<sup>{}^{</sup>a}$ [1] = 0.16 M;  ${}^{b}$ In entry 1, this ratio was obtained on heating the crude products with DBU (20 mol%) in hot THF (60 °C, 5 h); the dr ratio of this crude product is 44:44;6:6; <sup>c</sup>Product yields are reported after purification from a silica column.

Published on 25 October 2017. Downloaded by University of Newcastle on 26/10/2017 06:12:44

Published on 25 October 2017. Downloaded by University of Newcastle on 26/10/2017 06:12:44

#### Journal Name

solution was added ethyl acrylate (4 equiv) to complete an alkene/nitrone cycloaddition (eq. 6).

We investigated the scope of these new cascade [3+2]/[3+2]-annulations using nitrosobenzene, various allenes and electron-deficient olefins such as enones and acrylates; the results are summarized in Table 1. Styrenes failed with these reactions. Herein, resulting products 5b-5j followed a stereochemical course like that of parent species 5a. Among compounds 5a and 5b-5f, their major or single diastereomeric products have similar <sup>1</sup>H NMR patterns, indicative of the same stereochemistry. This hypothesis is confirmed by X-ray diffraction<sup>12</sup> of alcohol **5c'** derived from compound **5c**. For phenylallene 1a, their N-O annulation products 4 were difficult to purify, but were trapped with unsaturated esters and ketones to afford bis(isoxazolidine) species 5b-5d in satisfactory diastereoselectivity (dr = 4.2:1 and 6.1:1). In entry 1, crude product 5b was obtained in four diastereomers with a ratio 44:44:6:6; these isomeric mixtures were subsequently converted to two diastereomers in a ratio 4.2:1 through a DBU-catalyzed epimerization. For 3-phenyl, methyl and nbutyl-substituted phenylallenes, their resulting bis(isoxazolidine) compounds 5h-5k were obtained with satisfactory yields and high diastereoselectivities in most instances (entries 7-9).



For bis(isoxazolidine) **6a**, one of the two the isoxazolidine rings was selectively cleaved with H<sub>2</sub>. An initial treatment of this species with LiAlH<sub>4</sub> (3 equiv) afforded crude alcohol **6a** that was further reduced with Pd/C/H<sub>2</sub>(1 bar) in MeOH (23 °C) to yield monocyclic isoxazolidine **6a-H** as a single diastereomer (dr > 20:1, eq 7). In this transformation, the alcohol of **6a** is coordinated on the Pd surface to facilitate a reductive cleavage of its proximate isoxazolidine ring. To achieve a cleavage of two N-O rings, we treated compounds **5a** and **5i** with Pd/C/H<sub>2</sub> (1 bar)<sup>15</sup> in MeOH under reflux (5 h) to produce the corresponding lactams **5a-H** and **5i-H** efficiently; the molecular structure of compound **5a-H** was characterized with x-ray diffraction (eq 8).<sup>12</sup>

The utility of these cascade annulations is significantly expanded by their applicability to readily available 1-allenyl-5ene **7a**,<sup>16</sup> which reacted well with nitrosobenzene (4 equiv) in THF (25 °C, 1 h) to afford azacyclic product **8a** as a single dia-



-stereomer (eq 9). The stereochemical course of these N-O annulations, as depicted in **TS-2**, is exactly the same as those (**TS-1**) in their intermolecular fashions. The molecular structures of this annulation product **8a** was elucidated by X-ray diffraction.<sup>12</sup>

The scope of this intramolecular four-component annulation was compatible with various nitrosoarenes (**2b-2f**) to yield desired bis(isoxazolidine) species **8b-8f** as single diastereomers; the results are summarized in Table 2. Herein, products **8a-8e** were obtained in 52-68% yields because their frameworks are very strained with three five-membered rings fused together. For nitrosobenzenes **2b–2d** bearing electronwithdrawing (-Cl, -Br) and electron donating (-CH<sub>3</sub>) groups at





<sup>*a*</sup>[**7a**] = 0.10 M, [**2**] = 4 equiv; <sup>*b*</sup>Product yields are reported after purification from a silica column.

the *para*-phenyl positions, their reactions with 1-allenyl-5-ene **7a** yielded desired products **8b–8d** in 61–68 % yields (entries 1–3). Under similar conditions, *ortho* and *meta*-substituted chlorophenyl nitroso species **2e** and **2f** yielded desired bisisoxazolidines **8e** and **8f** in 52 % yields (entries 4-5).

We expanded the scope of this cascade annulation with various 1-allenyl-5-enes under optimum conditions. Table 3 (entry 1) shows the suitability of this annulation reaction for substrates **7b** bearing a *trans*-propenyl ( $R^4 = Me, R^3 = H$ ), yielding desired **8g** in 67 % yield; the two *trans*-CH-CHMe protons of compound **8g** are indicated from the <sup>1</sup>H NOE experiments. Such a stereochemistry is consistent with typical alkene/nitrone cycloadditions through a concerted pathway.<sup>17</sup> The reaction scope was extendible to additional substrates **7c** and **7d** bearing different alkyl and aryl substituents ( $R^1 = Me, R^3 = R^4 = Me$ ;  $R^1 = Ph, R^2 = H, R^3 = R^4 = Me$ ), yielding desired

Published on 25 October 2017. Downloaded by University of Newcastle on 26/10/2017 06:12:44

products **8h** and **8i** in 60–70 % yields (entries 2 and 3); herein, compound **8i** was present as a mixture of two diastereomers (dr = 4:3). The sterically hindered substrate **7e** ( $R^1=R^2=R^3=R^4=$  CH<sub>3</sub>) was also compatible to this annulation reaction; thus giving the desired azacyclic product **8j** in good yield (60 %, entry 4). For substrate bearing long chain alkyl group **7f** ( $R^1=n$ -Butyl,  $R^2=H$ ,  $R^3=R^4=$  CH<sub>3</sub>); their corresponding product **8k** was obtained in 51 % yield (entry 5). To enhance the further reaction scope, we synthesized additional

Table 3. Annulations with various 5-allenyl-1-enes.



a[7] = 0.10 M, [2] = 4 equiv; <sup>b</sup>Product yields are reported after purification from a silica column.

substrate 7g (R= Me); thus giving the desired product in 55% yield (entry 6).

Shown in eqs 10-11 are the reductive N-O cleavage of resulting bis(isoxazolidine) species **8a** and **8b** via treatment with Zn (20 equiv) in AcOH/MeOH/H<sub>2</sub>O at room temperatures,<sup>18</sup> yielding highly functionalized aminoalcohols **8a-H** and **8b-H** in 85% and 87% yields respectively. Two diastereomers were obtained for compounds **8a-H** because of an epimerization at the tertiary carbon center. We only



observedonediastereomericproductforcompoundonebearing a 4-CIC6H4NH group.DOI: 10.1039/C7OB02087B

# Conclusions

Stereoselective annulations between one allene, two nitrosoarenes and one electron-deficient alkene have been developed to yield bis(isoxazolidine) derivatives with high stereoselectivities. This reaction sequence involves an initial formation of isoxazolidin-4-imine oxides, followed by their dipolar [3+2]-cycloaddition with electron-deficient alkenes. Herein, exo-3,5-cycloadditions between isoxazolidin-4-imine oxides 4 and alkenes control the reaction stereoselectivity. To highlight the utility, the annulations of 5-alleneyl-1-enes with two nitrosoarenes were also tested, and bis(isoxazolidine) products were produced with excellent stereocontrol. Resulting bis(isoxazolidine) species derived from two distinct systems were reduced with Zn/MeOH to induce reductive N-O cleavages, yielding branched polyaminols stereoselectively.

# Experimental section

#### General Remarks

Unless otherwise noted, all reactions were carried out under a  $N_2$  atmosphere in reaction tube. Tetrahydrofuran was dried with sodium and benzophenone and distilled before use. Reagents were purchased from commercial sources and used without purification, unless otherwise stated. Reactions were magnetically stirred and monitored by thin layer chromatography carried out on 0.25 mm E. Merck silica gel plate ( $60_{f^-}$  254) using UV light as visualizing agents and/or potassium permanganate (KMnO<sub>4</sub>). <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker 400 MHz, Varian 400 MHz, Varian 500 MHz, Varian 600 and Varian 700 MHz spectrometers using chloroform-*d* (CDCl<sub>3</sub>) as the internal standard.

#### Standard procedure for synthesis of 5a:

A 10-mL flask was charged with nitrosobenzene **2a** (0.446 g, 4.17 mmol) under N<sub>2</sub>, and added with dry THF (3 mL); the resulting solution was cooled to 0 °C. To this solution was added a dry THF solution (3.5 mL) of compound **1g** (0.2 g, 1.04 mmol) before it was stirred for 3 h. To this solution was added ethyl acrylate (0.417 g, 4.17 mmol, 4 equiv); the resulting mixture was stirred for 12 h at 0 °C. The solution was then concentrated under reduced pressure, and purified on a silica column (10% ethylacetate/hexane,  $R_f = 0.7$  in 20% ethylacetate/hexane) to afford compound **5a** (0.44g, 0.885 mmol, 85%) as white solid.

#### Standard procedure for synthesis of 6a-H:

To a suspension of LiAlH<sub>4</sub> (0.023g, 0.592 mmol), in dry THF (10 mL) was added a solution of ethyl (*3S*,*5R*,*6S*,*9S*)-1,*6*,*8*,9-tetraphenyl-2,7-dioxa-1,8-diazaspiro-[4.4]nonane-3-arboxylate **5a** (100 mg, 0.197 mmol) in THF (2 mL) at 0 °C. After stirring at room temperature for 3 h, the reaction was quenched by the careful addition of water at 0 °C, then filtered through a celite bed, dried over anhydrous MgSO<sub>4</sub>, and concentrated to afford

crude ((35,58,65,95)-1,6,8,9-tetraphenyl- 2,7-dioxa-1,8-diazaspiro[4.4]nonan-3-yl)methanol **6a** as colorless liquid. To a methanol (3 mL) solution of **6a** was added to a suspension of 10% Pd/C (20.0 mg) in methanol (10 mL); the mixture was stirred under  $H_2$  (1 atm) at room temperature for 5 h. After a complete consumption of **6a**, the solution was filtered through a celite bed, concentrated, and the residues were purified by a flash silica column using 20% ethyl acetate/hexane as eluents, to give **6a-H** (0.072 g, 0.142 mmol, 78%) as pale yellow liquid.

## Standard procedure for synthesis of 8a:

To a dry THF solution (1 mL) of 1-(buta-1,2-dien-1-yl)-2vinylbenzene **7a** (0.1 g, 0.588 mmol) was added a dry THF solution (2 mL) of nitrosobenzene (0.25 g, 2.35 mmol, 4.0 equiv); the mixture was stirred at room temperature for 1 h, and evaporated under reduced pressure. The crude mixture was purified on a silica gel column (5% ethylacetate/hexane,  $R_f$ = 0.8) to afford compound **8a** (0.161 g, 0.43 mmol, 68%) as light brown solid.

**Spectral Data of Compound 5a:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>); δ 7.59 (d, *J* =7.6 Hz, 2H), 7.27 (t, *J* =6.8 Hz, 2H), 7.22 (d, *J* =6.8 Hz, 1H), 7.18-7.11 (m, 5H), 7.07-7.04 (m, 3H), 6.95 (d, *J* =8.4 Hz, 2H), 6.86 (t, *J* =7.2 Hz, 1H), 6.81 (d, *J* =8.0 Hz, 2H), 6.55 (d, *J* =7.2 Hz, 2H), 5.44 (s, 1H), 4.82 (s, 1H), 4.68 (dd, *J* =10.0, 4.0 Hz, 1H), 4.14-4.07 (m, 2H), 2.68 (dd, *J* =9.5, 4.0 Hz, 1H), 2.45-2.39 (m, 1H), 1.18 (t, *J* =7.1 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>); δ 170.4, 148.7, 147.2, 136.7, 136.1, 129.8, 128.6, 128.6, 128.1, 128.1, 127.8, 127.8, 127.7, 125.5, 122.5, 122.1, 116.5, 82.2, 79.3, 77.1, 76.8, 61.7, 41.1, 14.0; ESI-MS calcd for  $C_{32}H_{30}N_2NaO_4$  [M+Na]: 529.2103, found: 529.2105.

Spectral Data of Compound 5b: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); dr = 4.2:1; Major isomer; δ 7.30-7.29 (m, 3H) 7.28-7.26 (m, 3H), 7.25-7.24 (m, 2H), 7.23-7.20 (m, 4H), 7.18-7.16 (m, 3H), 5.34 (s, 1H), 4.33-4.32 (m, 1H), 4.28 (d, J =10.8 Hz, 1H), 4.21-4.18, (m, 2H), 3.41 (d, J =10.8 Hz, 1H), 2.46-2.37 (m, 2H), 1.28-1.25 (m, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); δ 170.9, 150.0, 146.0, 136.4, 128.9, 128.8, 128.5, 128.4, 127.1, 125.7, 122.2, 122.1, 115.2, 82.0, 80.8, 74.7, 63.2, 61.6, 41.5, 14.2; Minor isomer; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); δ 7.35-7.31 (m, 3H), 7.30-7.29 (m, 3H), 7.25-7.24 (m, 2H), 7.16-7.13 (m, 3H), 6.67-6.65 (m, 3H), 4.64 (s, 1H), 4.33 (d, J = 3.8 Hz, 1H), 4.21-4.18, (m, 2H), 4.19 (d, J = 10.8 Hz, 1H), 2.46-2.37 (m, 2H), 1.25-1.23 (m, 3H) other protons are merged; <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); δ 149.6, 129.0, 128.6, 128.1, 128.0, 125.4, 122.5, 121.6, 116.1, 73.7, 73.0, 72.5, 40.1 other carbons are merged or not visible; El<sup>+</sup>-MS calcd for C<sub>26</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub>[M+]: 430.1893, found: 430.1887.

**Spectral Data of Compound 5c:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>); *dr* = 6.1:1; Major isomer; δ 7.83 (d, *J* =7.6 Hz, 2H), 7.56-7.51 (m, 1H), 7.43-7.34 (m, 7H), 7.29-7.19 (m, 7H), 7.12 (t, *J* =7.6 Hz, 1H), 6.97 (d, *J* =8.4 Hz, 2H), 5.44 (s, 1 H), 4.93-4.89 (m, 1H), 4.13 (d, *J* =10.8 Hz, 1H), 3.41 (d, *J* = 10.8 Hz, 1H), 2.70-2.65 (m, 1H), 2.50-2.45 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>); δ 195.2, 150.0, 146.4, 136.4, 134.8, 133.7, 129.1, 128.8, 128.6, 128.5, 127.3, 125.4, 122.1, 121.6, 115.2, 83.3, 81.4, 78.1, 62.8, 39.9 two aromatic carbons merges with others; Minor isomer; <sup>1</sup>H

NMR (400 MHz, CDCl<sub>3</sub>); δ 6.88 (t, *J* =7.2 Hz, 2H),  $6_{A}$  ( $d_{cl}$  ( $\sigma_{a}$ ),  $\theta_{A}$ ),  $H_{2}$ , 2H), 4.86 (t, *J* =8.0 Hz, 1H), 4.76 (s, 1H); 4.33<sup>3</sup> (d, T=9.0 HZ, 1H), 4.10 (d, *J* =9.6 Hz, 1H) other protons are merged; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>); δ 128.1, 121.3, 116.1 other carbons are merged or not clearly visible; ESI- MS calc for C<sub>30</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>Na (M+Na): 485.1841, found: 485.1836.

**Spectral Data of Compound 5c':** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>); δ 7.41-7.36 (m, 7H), 7.28-7.22 (m, 8H), 7.19-7.04 (m, 7H), 6.97-6.92 (m, 3H), 5.42 (s, 1H), 4.36 (t, *J* =7.5 Hz, 1H), 4.21 (d, *J* =10.5 Hz, 1H), 3.40 (d, *J* =10.5 Hz, 1H), 3.28 (bs, 1H), 2.44 (dd, *J* =13.0, 8.0 Hz, 1H), 2.10 (dd, *J* =13.0, 7.0 Hz, 1H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>); δ 150.0, 145.8, 145.5, 143.4, 136.2, 128.8, 128.3, 128.3, 128.3, 128.1, 128.1, 127.4, 127.1, 126.9, 126.8, 125.3, 124.0, 122.1, 119.6, 115.2, 82.4, 80.6, 78.6, 78.1, 62.5, 40.6; ESI-MS calcd for  $C_{36}H_{33}N_2O_3$  [M+H]: 541.2491, found: 541.2481.

**Spectral Data of Compound 5d:** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); *dr* = 9.8:1; Major isomer; δ 7.31-7.22 (m, 7H), 7.17-7.15 (m, 2H), 7.13-7.10 (m, 2H), 7.01-6.96 (m, 3H), 5.35 (s, 1H), 4.20 (d, *J* =10.6 Hz, 1H), 3.97-3.95 (m, 1H), 3.45 (d, *J* =10.6 Hz, 1H), 2.53-2.49 (m, 1H), 2.43-2.40 (m, 1H), 2.33 (s, 3H), 2.26 (s, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); δ 209.2, 149.9, 145.6, 138.1, 133.6, 129.1, 128.8, 127.1, 124.9, 122.2, 120.7, 115.3, 81.9, 80.4, 80.1, 63.0, 40.9, 26.1, 21.2 one carbon merge with others; Minor isomer; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); δ 6.83-6.80 (m, 2H), 6.62-6.60 (m, 3H), 4.58 (s, 1H), 4.41 (d, *J* =9.6 Hz, 1H) other protons are merged; <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); 129.7, 128.5, 128.3, 127.9, 122.5, 120.5, 116.4, 79.1, 72.4, 72.1, 39.4 other carbons merged or not visible; ESI-MS calcd for  $C_{26}H_{27}N_2O_3$  [M+H]: 415.2022, found: 415.2016.

**Spectral Data of Compound 5e:** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>);  $\delta$  7.33-7.25 (m, 8H), 7.22 (d, *J* =8.3 Hz, 2H), 7.14-7.12 (m, 1H), 7.01-6.97 (m, 3H), 5.36 (s, 1H), 4.19 (d, *J* =10.6 Hz, 1H), 3.99-3.97 (m, 1H), 3.47 (d, *J* =10.6 Hz, 1H), 2.49-2.42 (m, 2H), 2.27 (s, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>);  $\delta$  209.0, 149.6, 145.4, 135.4, 134.1, 128.9, 128.9, 128.7, 128.5, 125.0, 122.4, 120.6, 115.4, 81.2, 80.2, 79.9, 63.0, 40.8, 26.1; ESI-MS calcd for C<sub>25</sub>H<sub>24</sub>ClN<sub>2</sub>O<sub>3</sub> [M+H]: 435.1475, found: 435.1477.

Spectral Data of Compound 5f: <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>); dr = 9:1; Major isomer; δ 7.31-7.23 (m, 6H), 7.19-7.17 (m, 2H), 7.13-7.09 (m, 1H), 7.00-6.96 (m, 3H), 6.86-6.83 (m, 2H), 5.33 (d, J = 2.2 Hz, 1H), 4.21 (dd, J = 18.5, 3.5 Hz, 1H), 3.98-3.94 (m, 1H), 3.79 (d, J = 3.7 Hz, 3H), 3.45 (dd, J = 18.6, 3.2 Hz, 1H), 2.52-2.48 (m, 1H), 2.45-2.40 (m, 1H), 2.26 (d, J = 3.9 Hz, 3H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>); δ 209.1, 159.5, 149.9, 145.7, 128.8, 128.5, 128.4, 124.9, 122.2, 120.7, 115.3, 113.8, 81.8, 80.3, 80.1, 63.0, 55.2, 40.8, 26.1 one carbon is merged; Minor isomer; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 6.61 (d, J =14.0 Hz, 3H), 4.55 (d, J = 2.4 Hz, 1H), 4.43 (dd, J = 17.2, 3.4 Hz, 1H), 3.80 (d, J =4.1 Hz, 3H), 2.37-2.32 (m, 2H), 2.25 (d, J = 3.9 Hz, 3H) other protons are merged; <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>); δ 129.2, 128.6, 128.3, 122.6, 120.5, 116.6, 114.3, 82.1, 72.2, 39.5, 25.8 other carbons merged or not visible; ESI-MS calcd for C<sub>26</sub>H<sub>26</sub>N<sub>2</sub>O<sub>3</sub>Na [M+Na]: 453.1790, found: 453.1795.

Published on 25 October 2017. Downloaded by University of Newcastle on 26/10/2017 06:12:44.

**Spectral Data of Compound 5g:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>); δ 7.62 (d, *J* =7.62 Hz, 2H), 7.38-7.33 (m, 2H), 7.28-7.26 (m, 2H), 7.20-7.12 (m, 7H), 7.09 (d, *J* =8.4 Hz, 2H), 7.04-7.01 (m, 2H), 6.99-6.95 (m, 1H), 6.67 (d, *J* =8.0 Hz, 2H), 5.37 (s, 1H), 4.47 (s, 1H), 4.25-4.21 (m, 1H), 2.44-2.39 (m, 1H), 2.18-2.14 (m, 1H), 2.12 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>); δ 206.2, 148.9, 147.2, 136.3, 136.1, 129.8, 128.7, 128.6, 128.4, 128.4, 128.2, 128.2, 127.8, 125.6, 123.3, 123.3, 117.9, 83.0, 82.0, 80.7, 80.6, 40.5, 27.5; EI-MS calcd for  $C_{31}H_{28}N_2NaO_3$  [M+Na]: 499.1998, found: 499.2004.

Spectral Data of Compound 5h: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); dr = 2.5:1; Major isomer;  $\delta$  7.73-7.71 (m, 3H), 7.62 (d, J = 7.9 Hz, 1H), 7.44-7.36 (m, 5H), 7.28-7.26 (m, 3H), 7.23-7.20 (m, 1H), 7.13-7.02 (m, 15H), 6.94 (d, J = 8.0 Hz, 2H), 6.86-6.84 (m, 1H), 6.67 (d, J = 7.5 Hz, 2H), 6.54 (d, J = 7.6 Hz, 1H), 5.54 (s, 1H), 5.20-5.18 (m, 1H), 4.61 (s, 1H), 3.00 (dd, J =13.4, 5.2 Hz, 1H), 2.47-2.39 (m, 1H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); δ 195.2, 148.6, 147.4, 136.9, 135.6, 134.6, 133.6, 129.9, 129.4, 128.8, 128.6, 128.6, 128.5, 128.4, 128.2, 127.7, 125.1, 124.5, 122.0, 117.5, 83.0, 81.4, 79.7, 78.2, 40.2 one carbon merged; Minor isomer;  $^{1}H$ NMR (600 MHz, CDCl<sub>3</sub>); δ 5.32 (s, 1H), 4.88-4.85 (m, 1H), 4.41 (s, 1H), 2.26-2.23 (m, 1H) other protons are merged; <sup>13</sup>C NMR (150 MHz, CDCl\_3);  $\delta$  194.6, 149.0, 147.6, 136.5, 136.2, 135.2, 133.8, 130.1, 129.2, 128.3, 128.1, 127.8, 126.1, 123.6, 122.8, 118.3, 84.0, 81.2, 80.8, 78.9, 38.9 other carbons merged or not visible; ESI-MS calcd for C<sub>36</sub>H<sub>30</sub>N<sub>2</sub>NaO<sub>3</sub> [M+Na]: 561.2154, found: 561.2153.

**Spectral Data of Compound 5i:** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); δ 7.50-7.48 (m, 2H), 7.38-7.35 (m, 4H), 7.27-7.26 (m, 2H), 7.21-7.20 (m, 3H), 7.14-7.11 (m, 2H), 6.91-6.90 (m, 2H), 5.48 (s, 1H), 4.43-4.40 (m, 1H), 4.25-4.19 (m, 2H), 3.60 (q, J = 6.5 Hz, 1H), 2.60-2.56 (m, 1H), 2.42 (dd, J = 9.6, 7.8 Hz, 1H), 1.37 (d, J = 6.5Hz, 3H), 1.27 (t, J = 7.1 Hz, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); δ 171.1, 148.0, 146.9, 138.1, 128.9, 128.7, 128.2, 127.9, 127.0, 124.3, 124.1, 121.2, 119.2, 81.8, 79.4, 74.8, 69.8, 61.6, 42.0, 14.1, 11.3; ESI-MS calcd for C<sub>27</sub>H<sub>28</sub>N<sub>2</sub>NaO<sub>4</sub> [M+Na]: 467.1947, found: 467.1941.

**Spectral Data of Compound 5j:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>); *dr* = 6.7:1; Major Isomer; δ 7.47-7.38 (m, 2H), 7.39-7.31 (m, 5H), 7.27-7.24 (m, 1H), 7.21-7.07 (m, 6 H), 6.90-6.88 (m, 2H), 5.50 (s, 1H), 4.64-4.57 (m, 1H), 4.23-4.18 (m, 2H), 3.63 (t, *J* = 6.0 Hz, 1H), 2.60-2.44 (m, 2H), 2.22-2.10 (m, 1H), 1.73-1.65 (m, 1H), 1.47-1.43 (m, 1H), 1.28-1.22 (m, 7H), 0.81 (t, *J* =9.0 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>); δ 171.1, 148.8, 147.1, 137.4, 128.9, 128.7, 128.1, 127.9, 127.4, 124.2, 124.0, 121.4, 119.0, 81.2, 79.9, 75.0, 73.2, 61.5, 41.9, 29.6, 27.6, 22.9, 14.1, 13.9; Minor Isomer; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>); δ 6.54 (d, *J* = 8.0 Hz, 2H), 5.32 (s, 1H), 0.88 (t, *J* =7.2 Hz, 3H) other protons are merged; <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>); δ 170.1, 147.9, 136.9, 125.6, 123.8, 122.6, 116.9, 82.2, 79.6, 73.7, 41.3, 28.4, 23.0, 14.0 other carbon are merged or not clearly visible; El<sup>+</sup>MS calcd for C<sub>30</sub>H<sub>34</sub>N<sub>2</sub>O<sub>4</sub> [M<sup>+</sup>]: 486.2519, found: 486.2517.

**Spectral Data of Compound 5a-H:** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); δ 7.75 (d, *J* =7.1 Hz, 2H), 7.54-7.52 (m, 2H), 7.48-7.45 (m, 1H), 7.39 (d, *J* =6.3 Hz, 2H), 7.33-7.24 (m, 8H), 7.04 (t, *J* =7.9 Hz, 2H),

# 6.69 (t, J = 7.2 Hz, 1H), 6.41 (d, J = 8.0 Hz, 2H), 5.84 (bs, 1H), 5.24 (d, J = 4.6 Hz, 1H), 4.75 (d, J = 2.4 Hz, 1H), 3.341 (bs, 2H), 2.92 (bs, 1H), 2.38 (t, J = 8.8 Hz, 1H), 2.04-1.98 (m, 2H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); $\delta$ 177.6, 146.2, 139.5, 138.8, 138.3, 129.7, 129.4, 129.1, 129.0, 129.0, 128.6, 128.5, 128.0, 118.7, 114.7, 83.5, 70.1, 67.1, 63.9, 39.9 two carbon merged with others; ESI-MS calcd for C<sub>30</sub>H<sub>29</sub>N<sub>2</sub>O<sub>3</sub> [M+H]: 465.2178, found: 465.2179.

**Spectral Data of Compound 5i-H**: <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); δ 7.48-7.43 (m, 5H), 7.39 (d, *J* =7.0 Hz, 2H), 7.33-7.29 (m, 3H), 7.18-7.16 (m, 2H), 6.80 (t, *J* =6.9 Hz, 1H), 6.46 (d, *J* =7.9 Hz, 2H), 5.37 (d, *J* =7.0 Hz, 1H), 4.64 (bs, 1H), 4.49-4.46 (m, 1H), 4.08 (d, *J* =6.1 Hz, 1H), 3.6 (d, *J* =9.9 Hz, 1H), 3.41 (bs, 1H), 2.31-2.27 (m, 1H), 2.04-2.00 (m, 1H), 1.20 (d, *J* =6.4 Hz, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); δ 176.8, 145.1, 140.0, 138.7, 129.5, 129.4, 129.4, 128.7, 128.4, 128.1, 119.8, 114.9, 80.8, 71.6, 68.1, 54.6, 36.9, 15.4; ESI-MS calcd for  $C_{25}H_{27}N_2O_3$  [M+H]: 403.2022, found: 403.2021.

**Spectral Data of Compound 6a-H:** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); δ 7.66 (d, *J* =7.5 Hz, 2H), 7.41-7.38 (m, 2H), 7.36-7.34 (m, 3H), 7.32-7.30 (m, 3H), 7.18 (t, *J* =7.5 Hz, 2H), 6.99 (dd, *J* =8.0, 1.0 Hz, 2H), 6.95 (t, *J* =7.7 Hz, 2H), 6.92-6.89 (m, 1H), 6.32 (d, *J* =8.5 Hz, 2H), 5.51 (s, 1H), 5.24 (s, 1H), 4.02 (bs, 1H), 3.67-3.65 (m, 1H), 3.10-3.04 (m, 2H), 1.99-1.91 (m, 2H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); δ 149.3, 144.8, 137.1, 136.5, 129.3, 128.9, 128.8, 128.8, 128.6, 128.4, 128.2, 121.8, 118.8, 117.1, 116.1, 86.3, 77.6, 71.5, 68.8, 66.9, 31.2 one carbon merged with others; ESI-MS calcd for  $C_{30}H_{31}N_2O_3$ [M+H]: 467.2335, found: 467.2334.

**Spectral Data of Compound 8a:** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); δ 7.53-7.51 (m, 2H), 7.38-7.35 (m, 1H), 7.33 (d, *J* =7.5 Hz, 1H), 7.30-7.27 (m, 5H), 7.24-7.22 (m, 3H), 7.13-7.10 (m, 1H), 6.94 (t, *J* =7.3 Hz, 1H), 5.74 (s, 1H), 4.42-4.39 (m, 1H), 4.31 (t, *J* =4.8 Hz, 1H), 3.93 (dd, *J* =8.3, 4.7 Hz, 1H), 3.46 (q, *J* =6.6, Hz, 1H), 1.40 (d, *J* =3.8 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>); δ 148.2, 147.0, 142.6, 140.3, 130.0, 128.7, 128.6, 128.4, 126.5, 125.5, 124.6, 121.6, 121.0, 117.4, 90.0, 82.9, 71.7, 71.2, 63.2, 12.6 ; ESI-MS calcd for  $C_{24}H_{23} N_2O_2$  [M+H]: 371.1759, found: 371.1755.

**Spectral Data of Compound 8b:** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); δ 7.45 (d, *J* =8.5 Hz, 2H), 7.38-7.37 (m, 1H), 7.31-7.28 (m, 2H), 7.24-7.23 (m, 5H), 7.15 (d, *J* =8.2 H, 2H), 5.67 (s, 1H), 4.38 (t, *J* =7.2 Hz, 1H), 4.28 (s, 1H), 3.90 (d, *J* =3.0 Hz, 1H), 3.36 (d, *J* =6.6 Hz, 1H), 1.34 (d, *J* =6.6 Hz, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); 146.6, 145.4, 142.3, 139.9, 131.0, 130.2, 128.8, 128.6, 126.7, 126.5, 124.7, 122.4, 118.6, 89.8, 83.0, 71.7, 71.4, 63.0, 12.4 one carbon merged; ESI-MS calcd for  $C_{24}H_{21}Cl_2N_2O_2[M+H]$ : 439.0980, found: 439.0981.

**Spectral Data of Compound 8c:** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>); δ 7.41-7.37 (m, 7H), 7.34-7.29 (m, 2H), 7.24-7.23 (m, 1H), 7.11-7.09 (m, 2H), 5.68 (s, 1H), 4.38 (t, *J* =5.0 Hz, 1H), 4.29 (t, *J* =4.5 Hz, 1H), 3.90 (dd, *J* =8.0, 4.5 Hz, 1H), 3.37 (q, *J* = 6.5 Hz, 1H), 1.35 (d, *J* =5.0 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>); 147.2, 145.9, 142.3, 139.8, 131.8, 131.5, 130.2, 128.6, 126.5, 124.7, 122.6, 118.9, 118.7, 114.1, 89.8, 82.9, 71.7, 71.3, 63.0, 12.4.; ESI-MS calcd for  $C_{24}H_{21}Br_2N_2O_2[M+H]$ : 526.9970, found: 526.9962.

**Journal Name** 

#### Journal Name

**Spectral Data of Compound 8d:** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$ 7.43 (d, *J* =8.5 Hz, 2H), 7.36 (t, *J* =7.0 Hz, 1H), 7.31-7.22 (m, 3H), 7.14-7.07 (m, 6H), 5.68 (s, 1H), 4.37 (t, *J* =7.0 Hz, 1H), 4.27 (t, *J* =4.0 Hz, 1H), 3.93 (dd, *J* =8.0, 4.0 Hz, 1H), 3.41 (q, *J* = 6.5 Hz, 1H), 2.28 (s, 3H), 2.29 (s, 3H), 1.35 (d, *J* =6.5 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>); 145.7, 144.8, 142.9, 140.5, 135.4, 131.1, 129.9, 129.3, 129.1, 128.3, 126.4, 124.6, 121.3, 117.8, 89.9, 82.9, 71.6, 71.2, 63.1, 20.9, 20.6, 12.4; ESI-MS calcd for C<sub>26</sub>H<sub>27</sub>N<sub>2</sub>O<sub>2</sub>[M+H]: 399.2073, found: 399.2076.

**Spectral Data of Compound 8e:** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>); δ 7.52 (t, *J* =2.0 Hz, 1H), 7.42-7.29 (m, 4H), 7.26-7.24 (m, 2H), 7.24-7.19 (m, 3H), 7.11-7.08 (m, 2H), 6.90 (dd, *J* =8.0, 1.5 Hz, 1H), 5.72 (s, 1H), 4.39 (t, *J* =7.5 Hz, 1H), 4.31 (t, *J* =4.5 Hz, 1H), 3.90 (dd, *J* =8.0, 4.5 Hz, 1H), 3.43 (q, *J* =6.5 Hz, 1H), 1.38 (d, *J* =6.5 Hz, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); 149.3, 147.9, 142.3, 139.8, 134.6, 134.5, 130.3, 129.7, 129.6, 128.7, 126.6, 125.6, 124.7, 121.4, 120.9, 119.3, 116.9, 115.3, 89.8, 83.1, 71.8, 71.2, 63.1, 12.5; ESI-MS calcd for  $C_{24}H_{21}Cl_2N_2O_2[M+H]$ : 439.0980, found: 439.0975.

**Spectral Data of Compound 8f:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>); δ 7.39-7.36 (m, 3H), 7.32-7.27 (m, 4H), 7.24-7.22 (m, 1H), 7.17-7.11 (m, 1H), 7.09-6.96 (m, 3H), 5.49 (s, 1H), 4.59 (dd, *J* =8.0, 3.9 Hz, 1H), 4.50 (t, *J* =8.0 Hz, 1H), 4.27 (q, *J* =6.8 Hz, 1H), 4.09 (dd, *J* =8.0, 4.0 Hz, 1H) 1.18 (d, *J* =6.8 Hz, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>): δ 144.7, 144.4, 143.4, 140.7, 132.6, 130.8, 130.2, 129.8, 128.3, 127.5, 127.2, 126.5, 126.1, 125.5, 125.3, 124.1, 121.6, 90.5, 84.2, 72.6, 67.8, 62.8, 11.6 one carbon merged; ESI-MS calcd for  $C_{24}H_{21}Cl_2N_2O_2[M+H]$ : 409.0980, found: 439.0976.

**Spectral Data of Compound 8g:** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); δ 7.40 (d, *J* =8.3 Hz, 2H), 7.35-7.27 (m, 7H), 7.24-7.19 (m, 3H), 7.10 (t, *J* =7.3 Hz, 1H), 6.91 (t, *J* =7.3 Hz, 1H), 5.81 (s, 1H), 3.93-3.91 (m, 1H), 3.81 (d, *J* =8.2 Hz, 1H), 3.32 (q, *J* =6.4 Hz, 1H), 1.59 (d, *J* =6.0 Hz, 3H), 1.40 (d, *J* =6.0 Hz, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); δ 148.4, 147.8, 141.0, 140.3, 129.6, 128.7, 128.6, 126.9, 125.3, 124.2, 121.1, 120.8, 116.3, 92.8, 82.8, 80.1, 70.8, 68.4, 17.0, 12.0 one carbon merged; ESI-MS calcd for  $C_{25}H_{25}N_2O_2[M+H]$ : 385.1916, found: 385.1908.

**Spectral Data of Compound 8h:** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); δ 7.57 (d, *J* =7.4 Hz, 2H), 7.40-7.20 (m, 10H), 7.14 (d, *J* =6.7 Hz, 1H), 6.87 (t, *J* =6.5 Hz, 1H), 5.95 (s,1H), 3.98 (s, 1H), 3.23 (d, *J* =4.8 Hz, 1H), 1.64 (s, 3H), 1.39 (d, *J* =4.6 Hz, 3H), 0.87 (s, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); δ 148.6, 147.6, 142.2, 139.4, 129.4, 128.7, 128.4, 126.3, 125.6, 125.0, 121.3, 119.6, 115.3, 91.4, 82.5, 81.5, 77.8, 71.3, 70.5, 26.6, 23.0, 12.0; ESI-MS calcd for  $C_{26}H_{27}N_2O_2[M+H]$ : 399.2073, found: 399.2067.

**Spectral Data of Compound 8i:** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); dr = 4:3; Major isomer;  $\delta$  7.52-7.51 (m, 1H), 7.43-7.40 (m, 3H), 7.38-7.36 (m, 2H), 7.35-7.32 (m, 3H), 7.28-7.23 (m, 5H), 7.10-7.08 (m, 2H), 7.04-7.01 (m, 1H), 6.93-6.91 (m, 1H), 6.82-6.80 (m, 1H), 6.17 (s, 1H), 4.31 (s, 1H), 4.14 (s, 1H), 1.46 (s, 3H), 0.71 (s, 3H), <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>);  $\delta$  149.1, 147.5, 142.9, 138.3, 134.4, 129.4, 129.0, 128.4, 128.3, 128.0, 126.5, 124.6, 124.1, 121.8, 119.6, 119.3, 114.8, 114.6, 92.7, 85.5, 82.5, 82.1,

78.7, 70.1, 25.8, 22.7; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)<sub>icc</sub>Minor isomer; δ 7.52-7.51 (m, 1H), 7.43-7.40 (m): 3H))  $\mathcal{P}$  38.79360 (m, 1H), 7.35-7.32 (m, 3H), 7.28-7.23 (m, 5H), 7.20-7.18 (m, 1H), 7.07-7.04 (m, 1H), 6.94-6.93 (m, 1H), 6.85-6.84 (m, 1H), 6.65-6.62 (m, 1H), 5.63 (s, 1H), 5.12 (s, 1H), 4.13(s, 1H), 1.53 (s, 3H), 0.81 (s, 3H) other peaks merge with others; <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); δ 149.4, 147.1, 143.6, 133.0, 129.6, 129.2, 128.7, 128.5, 126.2, 124.8, 119.8, 115.0, 92.0, 82.4, 73.1, 68.4, 26.1, 23.2 Other peaks merged; ESI-MS calcd for C<sub>31</sub>H<sub>28</sub>N<sub>2</sub>O<sub>2</sub> [M+]: 460.2151, found: 460.2148.

**Spectral Data of Compound 8j:** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>); δ 7.34-7.24 (m, 5H), 7.23-7.14 (m, 3H), 7.02-6.98 (m, 3H), 6.84 (t, J =8.4 Hz, 2H), 6.62 (t, J =6.0 Hz, 1H), 5.48 (s, 1H), 3.99 (s, 1H), 1.63 (s, 3H), 1.55 (s, 3H), 1.32 (s, 3H), 0.82 (s, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>); 149.4, 147.4, 143.1, 140.7, 128.7, 128.1, 125.7, 123.5, 121.4, 119.4, 115.0, 114.7, 94.9, 83.5, 83.0, 72.5, 67.4, 26.4, 24.3, 22.9, 21.6 other carbons are merged; El<sup>+</sup>-MS calcd for C<sub>27</sub>H<sub>28</sub>N<sub>2</sub>O<sub>2</sub>[M+]: 412.2151, found: 412.2154.

**Spectral Data of Compound 8k:** <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>);  $\delta$  7.45 (dd, *J* =8.0, 1.0 Hz, 2H), 7.35 (dd, *J* =8.0, 2.8 Hz, 1H), 7.29-7.25 (m, 4H), 7.24-7.23 (m, 1H), 7.19 (d, *J* =7.1 Hz, 2H), 7.16-7.13 (m, 2H), 7.06-7.02 (m, 1H), 6.84-6.80 (m, 1H), 5.96 (s, 1H), 4.07 (s, 1H), 3.25 (dd, *J* =7.3, 3.8 Hz, 1H), 2.07-2.02 (m, 1H), 1.64-1.63 (m, 1H), 1.60-1.52 (m, 5H), 1.29-1.20 (m, 2H), 0.80 (t, *J* =8.0 Hz, 3H), 0.71 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>); 149.3, 147.9, 142.0, 139.1, 129.4, 128.8, 128.5, 128.1, 126.5, 125.2, 124.3, 121.0, 119.3, 114.7, 91.7, 83.0, 82.6, 75.5, 71.0, 29.1, 28.1, 26.2, 23.0, 22.9, 14.0; ESI-MS calcd for C<sub>29</sub>H<sub>33</sub>N<sub>2</sub>O<sub>2</sub>[M+H]: 441.2542, found: 441.2535.

**Spectral Data of Compound 8I:** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>); δ 7.55 (dd, *J* =7.1, 1.0 Hz, 2H), 7.28-7.26 (m, 3H), 7.24-7.22 (m, 3H), 7.16-7.14 (m, 2H), 7.12-7.10 (m, 1H), 7.06 (d, *J* =12.0 Hz, 1H), 6.85-6.82 (m, 1H), 5.88 (s, 1H), 3.91 (s, 1H), 3.19 (q, *J* = 6.0 Hz, 1H), 2.33 (s, 3H), 1.60 (s, 3H), 1.35 (d, *J* =6.0 Hz, 3H), 0.83 (s, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>); δ 148.5, 147.6, 142.2, 138.5, 136.5, 130.4, 128.6, 128.4, 126.7, 125.7, 124.8, 121.4, 119.5, 115.2, 91.6, 82.4, 81.5, 71.2, 70.1, 26.6, 23.0, 21.3, 12.0. ESI-MS calcd for  $C_{27}H_{28}N_2O_2[M+]$ : 412.2151, found: 412.2156.

**Spectral Data of Compound 8a-H:** <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>); *dr* = 3:1; Major isomer; δ 7.40-7.28 (m, 3H), 7.22-7.20 (m, 4H), 7.18-7.06 (m, 3H), 6.95-6.88 (m, 2H), 6.75 (d, *J* =8.0 Hz, 2H), 5.8 (s, 1H), 4.04-4.03 (m, 1H), 3.96 (t, *J* =3.5 Hz, 2H), 3.80 (t, *J* =5.0 Hz, 1H), 1.01 (d, *J* =6.0 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>); δ 145.2, 143.2, 139.3, 129.6, 128.7, 128.2, 124.2, 123.6, 121.3, 119.8, 117.8, 116.0, 80.0, 73.1, 64.6, 55.9, 51.5, 15.3; Minor isomer; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>); δ 7.40-7.28 (m, 3H), 7.22-7.20 (m, 4H), 7.18-7.06 (m, 3H, ), 6.82-6.77 (m, 2H), 6.45 (d, *J* =7.5 Hz, 2H), 5.63 (s, 1H), 4.50 (dd, *J* =6.5, 1H), 4.0-3.99 (m, 2H), 3.63 (q, *J* =4.0 Hz, 1H), 1.05 (d, *J* =7.0 Hz, 3H); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>); δ 129.5, 129.4, 128.8, 124.3, 121.9, 118.4, 117.1, 82.9, 71.2, 65.0, 51.2, 13.9 other carbons are merged or not visible ESI-MS calcd for C<sub>24</sub>H<sub>27</sub>N<sub>2</sub>O<sub>2</sub>[M+H]: 375.2070, found: 375.2072.

#### Journal Name

**Spectral Data of Compound 8b-H:** <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>);  $\delta$ 7.34 (d, *J* =7.4 Hz, 1H), 7.31-7.25 (m, 2H), 7.16-7.13 (m, 3H), 7.07 (dd, *J* =6.8, 2.0 Hz, 2H), 6.98 (dd, *J* =6.7, 2.2 Hz, 2H), 6.51 (dd, *J* =6.8, 2.0 Hz, 2H), 5.75 (s, 1H), 3.96-3.89 (m, 4H), 3.60 (t, *J* =4.3 Hz, 1H), 1.0 (d, *J* =6.5 Hz, 3H); <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>);

144.1, 143.7, 143.2, 139.2, 129.3, 129.2, 128.8, 128.3, 125.8, 125.0, 124.1, 123.6, 120.5, 117.3, 80.2, 73.1, 64.3, 54.0, 51.9, 16.2; ESI-MS calcd for  $C_{24}H_{25}Cl_2N_2[M+H]$ : 443.1293 found: 443.1290.

# Acknowledgements

ARTICLE

The authors wish to thank the National Science Council, Taiwan, and the Ministry of Education, Taiwan for support of this work.

# Notes and references

- 1 For the reviews of radical annulations, see: (a) A. Studer and D. P. Curran, Angew. Chem. Int. Ed. 2016, **55**, 58; (b) H. Togo, Advanced free radical reactions for organic synthesis, Amsterdam: Elsevier, Boston, 1st ed., 2004; (c) T. R. Rheault and M. P. Sibi, Synthesis 2003, **6**, 803; (d) A. J. McCarroll and J. C. Walton, J. Chem. Soc., Trans. 1 2001, 3215; (e) P. Dowd and W. Zhang, Chem. Rev. 1993, **93**, 2091.
- For carbon-based 1,*n*-diradicals, see selected reviews: (*a*) H. Y. Lee, Acc. Chem. Res. 2015, **48**, 2308; (*b*) M. Abe, Chem.
   Rev. 2013, **113**, 7011; (*c*) P. W. Peterson, R. K. Mohamed and
   I. V. Alabugin, Eur. J. Org. Chem. 2013, 2505; (*d*) M. Abe, J. Ye and M. Mishima, Chem. Soc. Rev. 2012, **41**, 3808.
- For diradicals from diazo reagents, see: (a) W. Adam, S. Grabowski and H. Platsch, J. Am. Chem. Soc. 1989, 111, 751; (b) W. Adam, K. Hannemann and R. M. Wilson, J. Am. Chem. Soc. 1986, 108, 929; (c) W. Adam, K. Hannemann and R. M. Wilson, J. Am. Chem. Soc. 1984, 106, 7646; (d) W. R. Roth, M. Biermann, G. Erker, K. Jelich, W. Gerhartz and H. Görner, Chem. Ber. 1980, 113, 586.
- 4 (a) J. Drujon, R. Rahmani, V. Heran, R. Blanc, Y. Carissan, B. Tuccio, L. Commeiras and J. Parrain, *Phys. Chem. Chem. Phys.* 2014, **16**, 7513; (b) R. Roth, T. Ebbrecht and A. Beitat, *Chem. Berr.* 1988, **121**, 1357; (c) W. R. Roth, R. Longer, M. Bartmann, B. Stevermann, G. Maier, H. P. Reisenauer, R. Sustmann and W. Müller, *Angew. Chem. Int. Ed.* 1987, **26**, 256; (d) W. R. Roth, B. P. Scholz, R. Breuckmann, K. Jelich and H. W. Lennartz, *Chem. Ber.* 1982, *115*, 1934; (e) W. R. Roth and B. P. Scholz, *Chem. Ber.* 1982, *115*, 1197.
- 5 (a) R. R. Jones and R. G. Bergman, J. Am. Chem. Soc., 1972,
  94, 660; (b) R. Nagata, H. Yamanaka, E. Okazaki and I. Saito, Tetrahedron Letters, 1989, 30, 4995; (c) A. G. Myers, E. Y. Kuo, and N. S. Finney, J. Am. Chem. Soc. 1989, 111, 8057; (d)
  A. G. Myers, and P. S. Dragovich, J. Am. Chem. Soc., 1989,
  111, 9130; (e) R. G. Bergman, Acc. Chem. Res., 1973, 6, 25;
  (f) A. Basak, S. Mandal and S. S. Bag, Chem. Rev. 2003, 103, 4077; (g) C. Raviola, S. Protti, D. Ravelli and M. Fagnoni, Chem. Soc. Rev., 2016, 45, 4364; (h) C. Wentrup, Acc. Chem. Res. 2011, 44, 393.
- 6 (a) Y. Yamamoto and H. Yamamoto, Angew. Chem. Int. Ed. 2005, 44, 7082; (b) B. S. Bodnar and M. J. Miller, Angew. Chem. Int. Ed. 2011, 50, 5630; (c) L. Brulíková, A. Harrison, M. J. Miller and J. Hlaváč, Beilstein J. Org. Chem. 2016, 12, 1949; (d) P. F. Vogt and M. J. Miller, Tetrahedron 1998, 54, 1317; (e) J. Streith and A. Defoin, Synthesis 1994, 1994, 1107; (f) Y. Yamamoto and H. Yamamoto, Eur. J. Org. Chem. 2006, 2031–

2043; (g) H. Yamamoto and N. Momiyama, Chem. Commun. 2005, 3514–3525. DOI: 10.1039/C70B02087B

- 7 (a) P. Sharma and R. -S. Liu, Org. Lett. 2016, 18, 412; (b) P. Sharma and R. -S. Liu, Chem. Eur. J. 2016, 22, 15881; (c) I. Chatterjee, R. Fröhlich and A. Studer, Angew. Chem. Int. Ed. 2011, 50, 11257; (d) A. Mukherjee, R. B. Dateer, R. Chaudhuri, S. Bhunia, S. N. Karad and R. -S. Liu, J. Am. Chem. Soc. 2011, 133, 15372.
- 8 (a) A. G. Leach and K. N. Houk, Org. Biomol. Chem. 2003, 1, 1389; (b) A. G. Leach and K. N. Houk, J. Am. Chem. Soc. 2002, 124, 14820.
- 9 A. Penon, G. Palmisano, Y. -L. Zhao, K. N. Houk, J. Volkman and K. M. Nicholas, J. Am. Chem. Soc. 2009, **131**, 653-661.
- 10 Part of this work is recently published; see: J. Liu, M. Skaria, P. Sharma, Y. -W. Chiang and R. -S. Liu, *Chem. Sci.* 2017, 8, 5482-5487.
- (a) A. Rescifina, M. A. Chiacchio, A. Corsaro, E. D. Clercq, D. Iannazzo, A. Mastino, A. Piperno, G. Romeo, R. Romeo and V. Valveri, J. Med. Chem. 2006, 49, 709; (b) A. Pinto, P. Conti, L. Tamborini and C. D. Micheli, Tetrahedron: Asymmetry, 2009, 20, 508; (c) W. Hartwig and L. Born, J. Org. Chem, 1987, 52, 4352; (d) Y. Nishimura, E. Shitara, H. Adachi, M. Toyoshima, M. Nakajima, Y. Okami and T. Takeuchi, J. Org. Chem. 2000, 65, 2; (e) Y. Hayashi and S. Ogasawara, Org. Lett. 2016, 18, 3426; (f) G. Righi, S. Ciambrone, C. Bonini and P. Campaner, Bioorg. Med. Chem, 2008, 16, 902.
- 12 Crystallographic data of compounds **5a**, **5c'**, **5a-H** and **8a** were deposited in Cambridge Crystallographic Data Center; **5a**, CCDC 1540300; **5c'**, CCDC 1540298, **5a-H**, CCDC 1540301 and **8a**, CCDC 1541215.
- 13 For cycloaddition of ketonitrones with alkenes, see selected examples: (a) T. B. Nguyen, A. Matel, R. Dhal and G. Dujardin, Org. Lett. 2008, 10, 4493; (b) T. Q. Tran, V. V. Diev, G. L. Starova, V. V. Gurzhiy and A. P. Molchanov, Eur. J. Org. Chem. 2012, 2054; (c) M. Burdisso, R. Gandolfi, P. Gandilfi and P. Grünanger, Tetrahedron, 1989, 45, 5579.
- 14 (a) M. Berthet, T. Cheviet, G. Dujardin, I. Parrot and J. Martinez, *Chem. Rev.*, 2016, **116**, 15235; (b) A. Badoiu, *Org. Biomol. Chem.*, 2012, **10**, 114; (c) L. Dong, C. Geng and P. Jiao, *J. Org. Chem.*, 2015, **80**, 10992; (d) S. A. Ali and M. Z. N. Iman, *Tetrahedron*, 2007, *63*, 9134.
- 15 S. Ghorpade and R. -S. Liu, Angew. Chem. Int. Ed. 2014, 53, 12885.
- 16 R. Chaudhuri, H. -Y. Liao and R. -S. Liu, Chem. Eur. J. 2009, 15, 8895.
- 17 Reviews for nitrone/alkene cycloadditions, see: (a) K. V. Gothelf and K. A. Jørgensen Chem. Rev. 1998, 98, 863; (b) H. Pellissier, Tetrahedron 2007, 63, 3235; (c) L. M. Stanley and M. P. Sibi, Chem. Rev. 2008, 108, 2887; (d) M. Kissanea and A. R. Maguire, Chem. Soc. Rev. 2010, 39, 845; (e) T. Hashimoto and K. Maruoka, Chem. Rev. 2015, 115, 5366; (f) R. Huisgen, Angew. Chem. Int. Ed. Engl. 1963, 2, 565; (g) P. N. Confalone and E. M. Huie, Org. React. 1988, 36, 1; (h) D. B. Huple, B. D. Mokar and R. -S. Liu, Angew. Chem. Int. Ed. 2015, 54, 14924.
- (a) R. K. Kawade and R.-S. Liu, Angew. Chem. Int. Ed. 2017, 56, 2035; (b) S. Chakrabarty, I. Chatterjee, B. Wibbeling, C. G. Daniliuc and A. Studer, Angew. Chem. Int. Ed. 2014, 53, 5964.

8 | J. Name., 2012, 00, 1-3